Adjuvant chemotherapy after gastric resection in node-positive cancer patients: A multicentre randomised study

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 549-552

  Neri, B ^a,d   De Leonardis, V ^a   Romano, S ^a   Andreoli, F ^a   Pernice, L M ^a   Bruno, L ^a   Borrelli, D ^b   Valeri, A ^b   Fabbroni, S ^b   Intini, C ^c   Cini, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Department of Surgery ^*  (Italy)

^c Medical Department   (Italy)

^d Oncological Day Hospital   (Italy)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Epidoxorubicin; Gastric cancer; Leucovorin; Randomised trial

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GASTRECTOMY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

EID: 9044225531     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.95     Document Type: Article

References (33)

1. ALEXANDER AR, KELSEN DP AND TEPPER JE. (1993). Cancer of the stomach. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S and Rosenberg SA (eds) pp. 818-848. JB Lippincott: Philadelphia.
2. ATIQ OT, KELSEN DP, SHIU MH, SALTZ L, TONG W, NIEDZWIECKI D, TROCHANOWSKI B, LIN S, TOOMASI F AND BRENNAN M. (1993). Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J. Clin. Oncol., 11, 425-433.
3. BALIKDJIAN D, VAN HOUTTE P AND LUSTMAN-MARECHAL J. (1980). Place de la radiotherapie dans le traitement post operatoire des tumeurs de l'estomac. Rev. Franc. Gastroenterol., 162, 496-504.
4. BLEIBERG H, GERARD B AND DEGUIRAL P. (1992). Adjuvant therapy in resectable gastric cancer. Br. J. Cancer, 66, 987-991.
5. BRUCKNER HW, CHESSER MR, WONG H AND MANDELI J. (1991). Folate biochemical modulation regimen for the treatment of gastric cancer. J. Clin. Gastroenterol., 13, 384-389.
6. BUNT AMG, HERMANS J, BOON MC, VAN DE VELDE CJH, SASAKO M, FLEUREN GJ AND BRUIJN JA. (1994). Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. J. Clin. Oncol., 12, 417-422.
7. COOMBES RC, SCHEIN PS, CHILVERS CE, WILS J, BERETTA G, BLISS JM, RUTTEN A, AMADORI D, CORTES-FUNES H AND VILLAR-GRIMALT A. (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol., 8, 1362-1368.
8. DE BRAUD E, BAJETTA E, DI BATOLOMEO M AND COLLEONI M. (1992). Adjuvant chemotherapy for cancer of gastrointestinal tract: a critical review. Tumori, 78, 228-234.
9. DECARLI L AND LA VECCHIA C. (1988). Cancer mortality in Italy. Tumori, 74, 6623-6632.
10. ENGSTROM PF, LAVIN PT, DOUGLASS HO AND BRUNNER KW. (1985). Post-operative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study. Cancer, 55, 1868-1873.
11. ESTAPÈ J, GRAU JJ, LOCOBENDAS F, CURTO J, DANIELS M, VIGNOLAS N AND PERA C. (1991). Mitomycin C as an adjuvant treatment to resected gastric cancer. Ann. Surg., 213, 219-221.
12. FINK U, SCHUHMACKER C, BOTTCHER K, BUSH R, DITTLER HJ, HELMBERGER H, BARTELS H, STEIN HJ AND SIEWERT JR. (1993). Neoadjuvant chemotherapy with Etoposide/Adriamycin and Cisplatin (EAP) in locally advanced gastric carcinoma. In Adjuvant Therapy of Cancer VII, Salomon SE (ed) pp. 272-280. JB Lippincott: Philadelphia.
13. HAIM N, COHEN V AND HONIGAM J. (1982). Treatment of advanced carcinoma with 5-fluorouracil, adriamycin and mitomycin. Cancer Chemother. Pharmacol., 8, 277-280.
14. HAVLIN KA AND MACDONALD JS. (1992). Gastric cancer: chemotherapy of advanced disease. In Gastrointestinal Oncology, Algren JD, Macdonald JS (eds) pp. 171-179. JB Lippincott: Philadelphia.
15. HERMANS J, BONENKAMP JJ, BOON MC, BUNT AMG, OHYAMA S, SASAKO M AND VAN DE VELDE GJH. (1993). Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomised trials. J. Clin. Oncol., 11, 1441-1447.
16. INTERNATIONAL UNION GAINST CANCER. (1987). Classification of Malignant Tumours, Hermanek P and Sobin LH (eds). Springer: Geneva.
17. KAPLAN EL AND MEIER P. (1958). Non parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53, 457-481.
18. KORNEK U, SCHULZ F, DEPISH D, ROSEN H, KWASNY W, SEBESTA C AND SCHEITHAUER W. (1992). A phase I-II study of epirubicin, 5-fluorouracil and leucovorin in advanced adenocarcinoma of the stomach. Cancer, 71, 2177-2180.
19. MACDONALD JS, SCHEIN PS, WOOLLEY PV, SMYTHE T, UENO W AND HORT D. (1980). 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann. Intern. Med., 93, 533-536.
20. MICHELASSI F, TAKANISHI DM, PANTALONE D, HART J, CHAPPELL R AND BLOCK GE. (1994). Analysis of clinicopathologic prognostic features in patients with gastric adenocarcinoma. Surgery, 116, 804-810.
21. MILLER AB, HOOGSTRATEN B, STAQUET M AND WIKLER A (1981). Reporting results of cancer treatment. Cancer, 47, 207-214.
22. MURAD AM, SANTIAGO FF, PETROIANU A, ROCHA PR, RODRIGUES MA AND RAUSCH M. (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41.
23. NERI B, GEMELLI MT, LOTTINI G, SAMBATARO S, FABBRONI S, LOTTINI L AND BRUNO S. (1992). Epidoxorubicin, high dose leucovorin and 5-Fluorouracil in advanced measurable gastric cancer: a phase II study. Anticancer Res., 12 (suppl. 6A), 1927.
24. NERI B, GEMELLI MT, ANDREOLI F, BRUNO S, FABBRONI S, LEONE V, VALERI A AND BORRELLI D. (1993). Epidoxorubicin and high dose leucovorin plus 5-fluorouracil in advanced gastric cancer. Anti-Cancer Drugs, 4, 323-326.
25. OGAWA M AND TAGUCHI T. (1990). Upper gastrointestinal tumors. In Cancer Chemotherapy and Biological Response Modifiers, Pinedo HM, Chabner BA and Longo DL (eds) pp. 456-459. Elsevier.
26. PREUSSER P, WILKE H, ACHTERRATH W, FINK U, LENAZ A, HEINICKE A, MEYER J AND BUENTE H. (1989). Phase I study of a combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol., 7, 1310-1317.
27. ROUGIER P, LASSER P, DUCREUX M, MAHJOUBI M, BOGNEL C AND ELIAS D. (1994). Preoperative chemotherapy of locally advanced gastric cancer. Ann. Oncol., 5, 59-68.
28. SIMON R. (1985). Size of phase III cancer clinical trials. Cancer Treat. Rep., 69, 1087-1093.
29. SAS INSTITUTE INC. (1987). SAS/STAT Guide for Personal Computers, Version 6 edn. SAS Institute: Cary, NC.
30. THE GASTROINTESTINAL TUMOR STUDY GROUP. (1982). Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer, 49, 1116-1122.
31. WAXMAN ASJ. (1992). Chemotherapy for gastric cancer. Gut, 33, 1153-1154.
32. WILKE H, PREUSSER P, FINK U, GUNZER U, MEYER HJ, SIEWERT JR, ACHTERRATH W, LENAZ L, KNIPP H AND SCHMOLL HJ, (1989). Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with Etoposide, Doxorubicin and Cisplatin. J. Clin. Oncol., 7, 1318-1326.
33. WILS J, MEYER HJ AND WILKE H. (1994). Current status and future directions in the treatment of localized gastric cancer. Ann. Oncol., 5, 69-72.